Table 9.
The Effect of Growth Hormone Therapy on Motor Function of Patients after Traumatic Brain Injury (TBI)
| Author | Design | Severity | No. of patients with treatment | No. of patients without treatment | Treatment beginning and length (months) |
Upper extremity motor speed | FIM | Activities in daily life | p value in the treated group from baseline | p value between treated and untreated groups |
|---|---|---|---|---|---|---|---|---|---|---|
| High et al.30 | RCT | Moderate-to-severe. GCS: 5.8 (SD: 3.4) | 12 | 11 | Chronic, 12 | X | <0.01 | <0.01 | ||
| Dubiel et al.29 | RCT | All severities GOSE score: 3-17 | 16 | 18 | Acute, 6 | X | <0.05 | |||
| Moreau et al.33 | Cohort study | All severities GCS: 8.1 (SD: 5.1) | 23 | 27 | Chronic, 12 | X | 0.001 | n.s. | ||
| Bhagia et al.37 | Case report | No GCS assessed | 1 | Chronic, 12 | X | improvement |
Motor function was assessed by Functional Independence Measure test (FIM), and by quantifying upper extremity motor speed and daily activities. Acute treatment was started within 1 month after TBI. Statistical significance is indicated at p < 0.05.
RCT, randomized controlled trial; n.s., non-significant; GCS, Glasgow Coma Scale; GOSE, Glasgow Outcome Score-Extended.